Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
leukemia-specific T cells
- Development stage
- Unknown
- Lead developer
- Baylor College of Medicine
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Leukemia-specific T cells, also known as mLSTs, are a cell therapy developed by Baylor College of Medicine. These are stem cell donor-derived T cells that are selectively activated and expanded to react to multiple antigens expressed by acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) cells, specifically PRAME, WT1, Survivin, and NY-ESO-1. The therapy is designed to selectively recognize and kill leukemia antigen-pulsed cells without activity against normal cells, thereby enhancing the graft-versus-leukemia (GVL) effect while minimizing graft-versus-host disease (GVHD). It is being investigated for the prevention and treatment of AML and MDS after allogeneic hematopoietic stem cell transplantation (HCT).
- Other names
- multiple leukemia antigen-specific T cellsstem cell donor–derived multiple leukemia antigen–specific T cells
02
Targets
WT1 (Wilms tumor protein)BIRC5 (Survivin)PRAME (Preferentially expressed antigen in melanoma)
Beyond the preview
Go deeper on leukemia-specific T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on leukemia-specific T cells.